NEWS AND MEDIA
Our Commitment to Safety as we Navigate Coronavirus
Mar 24, 2020
We have always been guided by our core values—Collaboration, Integrity, Courage, and Innovation—but now, facing the challenges posed by COVID-19, our core values have taken on new meaning. The health and safety of our colleagues, customers and community, along with the continuity of business operations – critical to serve patients who rely on our medicines and products – are our top priorities.
Our manufacturing facilities are open and operating but, where our workforce can work from home, they are doing so. We have taken special measures to protect those who continue to work on-site during this time, including enhanced cleaning, shift adjustments, social distancing, and business continuity planning, among other measures.
Our business remains open. Our products are available, and we have not identified any supply chain risks at this time. We continue to progress our public health initiatives and our pipeline. Please continue to contact us through your normal channels. Our medical team is available and if you have questions related to our products please contact us; 1-888-726-7535; www.AskPurdueMedical.com. Other contact information can be found here.
We are particularly concerned that the pandemic is triggering indirect health risks for people with (or those at risk of experiencing) substance use disorders. Through our office of Corporate Social Responsibility, Purdue is providing $500,000 in additional monetary support to local and national organizations focused on the pandemic, as well as those delivering harm reduction programs, improving access to medication-assisted treatment, and supporting continuity of recovery services during the pandemic.
We are confident that, by facing new challenges through a data-driven, health-conscious, and business continuity-focused lens, we can continue to serve those who rely on our medicines and products.
Speaking Out Against Systemic Racism
June 3, 2020
WE FEEL compelled at this moment to speak out about the unacceptable and disturbing acts of racial injustice that have brought our nation to an inflection point.
WE BELIEVE that any form of racism or racial suppression is wrong. We believe that addressing injustice must be a priority for us all. We believe that people have the right to protest peacefully. We believe that compassion and understanding happen only when we truly open our hearts and listen.
WE WILL do our part. We will continue to provide a safe and welcoming environment for our employees. We will foster an environment that encourages open dialogue, opportunities, and support for individuals from all backgrounds. We will not tolerate racial discrimination or harassment in our ranks. We will continue to support organizations that provide services for underserved populations in communities where we live, work and serve. And we will listen so we can do better in honoring these commitments.
Recent News
The Prescription Drug Safety Network Significantly Expands Its Reach in Year 2 and Reports an Average 48% Knowledge Gain Nationwide
Purdue announces expanded support for the Prescription Drug Safety course through an additional sponsorship in Tennessee STAMFORD, Conn. – August 20, 2019 — Purdue Pharma L.P. (“Purdue”), a founding member of the Prescription Drug Safety Network (“the Network”),…
Purdue Pharma L.P. and the National Center for Wellness & Recovery at Oklahoma State University Announce Collaboration Around Research to Address the Opioid Addiction Crisis
Company to provide access to data and intellectual property STAMFORD, Conn./TULSA, Okla., August 15, 2019 – Purdue Pharma L.P. (“Purdue”) and the National Center for Wellness & Recovery (the “Center”) at Oklahoma State University today announced an…
Julie Ducharme, BPharm, MSc, PhD Named Vice President and Chief Scientific Officer of Purdue Pharma L.P.
STAMFORD, CT, July 2, 2019 — Purdue Pharma L.P. today announced that Julie Ducharme, BPharm, MSc, PhD will be joining the organization as Vice President and Chief Scientific Officer with accountability to help progress its existing pipeline and identify new research…
Purdue Pharma Presents Considerations in Opioid Comparator Selection at the College on Problems of Drug Dependence Annual Scientific Meeting
STAMFORD, Conn., June 18, 2019 – Purdue Pharma L.P. presented a poster describing an approach to the evaluation of opioid comparators when assessing the effectiveness of abuse-deterrent formulations (ADFs) of extended-release opioids at the College on Problems of Drug…
Purdue Pharma Announces First Participant Enrolled in Clinical Study Assessing Nalmefene HCl Injection for the Emergency Treatment of Known or Suspected Opioid Overdose
NAL1002 study will examine pharmacokinetics, safety and tolerability of nalmefene HCl Company will not profit from nalmefene HCl injection Stamford, Conn. – June 6, 2019 – Purdue Pharma L.P. today announced the initiation and first participant enrollment in a Phase 1…
Eisai and Purdue Pharma Announce Buy Out of Purdue’s Rights in Worldwide Collaboration to Develop and Commercialize Lemborexant
WOODCLIFF LAKE, N.J. and STAMFORD, Conn. – April 30, 2019 – Eisai Inc. and Purdue Pharma L.P. today announced that Eisai will buy out Purdue’s rights to the worldwide collaboration for the development and commercialization of lemborexant, an investigational sleep-wake…
FDA Grants Competitive Generic Therapy (CGT) Designation to Purdue Pharma’s Investigational Nalmefene HCl Injection for the Emergency Treatment of Known or Suspected Opioid Overdose
Committed to advancing solutions to the opioid addiction crisis, Purdue will not profit from nalmefene HCl Stamford, Conn. – April 24, 2019 – Purdue Pharma L.P. today announced that the U.S. Food & Drug Administration (FDA)’s Office of Generic Drugs has granted…
Purdue Pharma Announces Landmark Agreement with Oklahoma to Advance the Treatment of Addiction
Settlement will establish national center for addiction studies and treatment in Tulsa; Sackler family announces voluntary contribution to support national center STAMFORD, Conn., March 26, 2019 — Purdue Pharma L.P. today announced that it has entered into a landmark…
FDA Grants Purdue Pharma’s Nalmefene HCl Injection Fast Track Designation for the Emergency Treatment of Known or Suspected Opioid Overdose
Committed to advancing solutions to the opioid public health crisis, Purdue will not profit from nalmefene HCl STAMFORD, Conn., March 13, 2019 — Purdue Pharma L.P. today announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track designation to…
Purdue Pharma Statement to 60 Minutes Regarding the Segment on Opioid Medicines Expected to Air Sunday, February 24, 2019
In 1995, the U.S. Food and Drug Administration (FDA) approved OxyContin® (oxycodone HCI) extended-release tablets CII (current Full Prescribing Information and Box Warning here)1 based on a robust set of clinical trials, which the FDA dubbed at the time the “gold…